Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…
Geron Commences Initial-Stage Rare Blood Cancer Combination Study
Geron Corporation (NASDAQ: GERN) has dosed first patient in IMproveMF study evaluating imetelstat in combination with ruxolitinib for patients with frontline myelofibrosis (MF).
HC Wainwright Cuts Price For This Small Cap ‘Reflecting Potential Pause In Hemophilia Program’
Earlier this month, Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) reported 2Q22 earnings focusing on the pipeline’s progress. Notably, the company said it…
Why Pharvaris Shares Are Plummeting Today?
The FDA verbally placed a clinical hold on Pharvaris NV’s (NASDAQ:PHVS) PHA121 in the U.S. under two Pharvaris Investigational New Drug (IND)…
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock
HC Wainwright increased the price target on Genmab A/S (NASDAQ:GMAB) from $49 to $51, with a Buy rating. The analyst cites that…
Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off
Kronos Bio (NASDAQ: KRON) has initiated patient dosing in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).
Minerva Seeks FDA Approval For Its Schizophrenia Candidate
Minerva Neurosciences Inc (NASDAQ:NERV) submitted a marketing application to the FDA for roluperidone for negative symptoms in patients with schizophrenia. “We…
Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here’s Who May Be Rolling Them Out
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have completed a submission to the FDA requesting Emergency Use Authorization for an omicron BA.4/BA.5-adapted COVID-19…
Belite Bio Starts Enrollment In Pivotal Lead Asset Study In Inherited Eye Disease
Belite Bio Inc (NASDAQ:BLTE) commenced enrollment for the U.S. Phase 3 trial of LBS-008 in patients with Stargardt Disease (STGD1), a…